Scientists at the Icahn School of Medicine at Mount Sinai have identified an important immune response that helps explain why some cancer patients benefit from immunotherapy while others do not.
In a study published in the January 27 online issue of Nature Medicine (DOI 10.1038/s41591-025-04177-6), the researchers found that antibody-producing immune cells called IgG1 plasma cells play a key role in helping patients respond to PD-1 immune checkpoint inhibitors.
PD-1 immune checkpoint inhibitors are a type of immunotherapy that helps the immune system recognize and attack cancer. They have transformed cancer care and are now a backbone of treatment across many tumor types. But not all patients experience durable benefit, and the biological reasons behind this variability are not completely…